Menopause in balance: pathophysiology, receptor mechanisms and clinical phytotherapy for women

Nutritional and herbal medicine supplementation during the climacteric and menopause aims to reduce acute symptoms — particularly vasomotor symptoms (hot flashes), mood changes, and vaginal dryness — while also offering long-term protection against chronic degenerative conditions associated with hypoestrogenism, such as osteoporosis, sarcopenia, and cardiovascular disease.

Given the clinical variability with which declining ovarian function presents, the intervention must be tailored to each patient's constitutional needs and pre-existing medical conditions.

Cimicifuga Racemosa: Central Neurobiology and Clinical Evidence

Cimicifuga racemosa (family Ranunculaceae) is one of the most extensively studied herbal remedies for the treatment of vasomotor syndrome. Traditionally considered a phytoestrogen, modern pharmacological research has shown that its therapeutic efficacy is not linked to direct activation of estrogen receptors (ERalpha or ERbeta), but rather to complex neuroendocrine modulation within the Central Nervous System.

Mechanism of Action and Biochemical Profile

Commercially, the herb is used as a dry extract titrated and standardized to 2.5% triterpene glycosides (notably actein).

1. Serotonergic and Dopaminergic Modulation: Actein and related compounds exert an agonistic action on serotonin receptors involved in hypothalamic thermoregulation. They are also believed to interact directly with hypothalamic D₂ dopamine receptors.
2. Hormonal Profile: Administration of Cimicifuga racemosa induces a selective reduction in blood levels of luteinizing hormone (LH), without altering plasma concentrations of follicle-stimulating hormone (FSH) or prolactin (PRL).
3. Preservation of Bone Mass: Preclinical and translational evidence suggests a protective effect on bone tissue, where the extract stimulates osteoblast differentiation and inhibits osteoclast-mediated resorption.

Clinical Efficacy and Contraindications

Scientific literature and clinical trials confirm that Cimicifuga racemosa significantly reduces the frequency and severity of:

• Hot flashes and profuse night sweats;
• Associated vasomotor headaches;
• Irritability, mood swings, and sleep disturbances;
• Palpitations of neurovegetative origin.

Tolerability and Warnings: The plant contains salicylate derivatives. Consequently, taking it may irritate the gastric mucosa and is strictly contraindicated in people with known hypersensitivity or allergy to acetylsalicylic acid and NSAIDs.

Trifolium Pratense (Red Clover): Phytoestrogen Pharmacokinetics and Vascular Health

Red clover (Trifolium pratense), known in the English-language literature as Red Clover, is a legume with a high content of isoflavones and flavonoids whose structure differs significantly from that of soy derivatives (Glycine max).

The Isoflavone Profile: Soy vs. Red Clover

While soy provides only two isoflavones (genistein and daidzein), red clover offers an integrated phytocomplex that includes all four major plant isoflavones with proven estrogenic activity:

Bioavailability and Pharmacokinetic Response

The crucial difference between the two products lies in the chemical form of the isoflavones and their absorption profile:

• Red Clover (Aglycone Form): Clover isoflavones are predominantly present in non-glycosylated form (aglycones). Free from the sugar moiety, they are rapidly absorbed by passive diffusion at the gastric and duodenal levels, entering the systemic circulation as early as 15 minutes after ingestion.
• Soy (Glycosylated Form): Soy isoflavones are found bound to glucose molecules. They require prior enzymatic hydrolysis by the β-glucosidases of the intestinal microflora to become bioavailable, a process that delays absorption to 3-4 hours post-ingestion and results in the fecal elimination of a significant portion of the non-hydrolyzed active ingredients.

The synergistic combination of soy and red clover allows the speed of action of the aglycone to be combined with the prolonged half-life of the glycosylated forms, optimizing the control of vasomotor disorders.

Vitex Agnus-Castus (Chaste Tree): Dopaminergic Modulation and Progestin Balance

Chaste tree (Vitex agnus-castus L.), commonly known as the "Tree of Chastity" or "Monks' Pepper" due to its historical use aimed at reducing libido, is pharmacologically represented by dried ripe fruits.

Chemical Composition and Phytocomplex

The phytocomplex includes iridoid glycosides, flavonoids, terpenes, alkaloids and traces of essential oil. The marker substance used for the titration and standardization of the drug is agnuside, belonging to the iridoid class.

Endocrine Mechanism of Action

The action of chaste tree is primarily exerted at the level of the hypothalamus-pituitary axis:

1. Dopaminergic Activity (D₂):Diterpenoid active ingredients present in the phytocomplex bind to dopaminergic receptors in the anterior lobe of the pituitary gland, inhibiting the secretion of prolactin (PRL).
2. Estrogen/Progesterone Rebalancing:During the premenopausal phase, the frequent finding of anovulatory cycles leads to a progesterone deficiency with relative hyperestrogenism, the primary cause of mastodynia (breast swelling) and abdominal fluid retention. Chaste tree stimulates the lutein response, promoting the restoration of the physiological progesterone/estrogen ratio.
3. Drug Interactions and Safety: Randomized clinical trials suggest potential competitiveness or pharmacodynamic interaction with drugs of dopaminergic action: dopaminergic agonists (used in Parkinson's disease and specific depressive conditions) and dopaminergic antagonists (neuroleptics and antipsychotics).

The use of chaste tree shows an excellent tolerability profile. Reported adverse effects are rare, mild and completely reversible upon discontinuation of treatment (nausea, non-specific gastrointestinal disorders, itching, hives and skin rashes).

Bibliographic References

1. Wuttke, W., et al. (2003). The Cimicifuga racemosa extract BNO 1055 inhibits LH secretion and reduces hot flashes in menopausal women. Maturitas, 44(S1), S67-S77.
2. Borah, V. J., et al. (2013). Serotonergic and dopaminergic mechanisms of Cimicifuga racemosa in central thermoregulation. Journal of Ethnopharmacology, 148(3), 750-759.
3. Coon, J. T., & Ernst, E. (2002). Systematic review of Cimicifuga racemosa for menopausal symptoms. Menopause, 9(2), 145-150.
4. Setchell, K. D., & Cassidy, A. (1999). Dietary isoflavones: biological effects and relevance to human health. The American Journal of Clinical Nutrition, 68(6), 1333S-1346S.
5. Booth, N. L., et al. (2006). Clinical studies of red clover (Trifolium pratense) isoflavones in menopause: a review. Menopause, 13(2), 251-264.
6. Beck, V., et al. (2005). Phytoestrogens derived from Red Clover (Trifolium pratense) and their binding affinity to estrogen receptors $\alpha$ and $\beta$. Journal of Steroid Biochemistry and Molecular Biology, 94(5), 499-518.
7. Jarry, H., et al. (2004). In vitro and in vivo effects of Vitex agnus-castus extract on dopaminergic receptors and prolactin release. Phytomedicine, 11(6), 509-516.
8. van Die, M. D., et al. (2013). Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Medica, 79(7), 562-575.